Conference Coverage

Reviews of presentations from professional meetings about brain metastases.

RSR 13 Plus Cranial Radiation Therapy Improves Survival in Patients With Brain Metastases Compared to RTOG Recursive Partitioning Analysis Brain Metastases Database
Presenter: E. Shaw Affiliation: Wake Forest University School of Medicine Background: RSR 13 is a potential enhancer of ionizing radiation by decreasing hemoglobin-O2 binding affinity and increasing tumor oxygenation. This is a Phase II open label study design to assess the efficacy/safety of RSR 13 plus external beam radiation

Randomized Treatment of Brain Metastasis with Gamma Knife Radiosurgery, Whole Brain Radiotherapy or Both
Presenter: P. B. Chougule Affiliation Rhode Island Hospital/Brown University, Providence, RI Summary: Brain metastases develop in approximately 25% of all cancer patients. Management with whole brain RT may palliated these patients, but survival remains dismal. This report is of a group of patients randomized to either whole brain RT

Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both
Presenter: P.B. Chougule Affiliation: Rhode Island Hospital, Brown University Summary: Whole brain radiation therapy (WBRT) has been the standard care for the majority of patients with brain metastasis. However, the outcome of these patients has been dismal due to both local and systemic failure. Stereotactic radiosurgery

Preliminary Report of RTOG 9508: A Phase III Trial Comparing Whole Brain Irradiation Alone Versus Whole Brain Irradiation Plus Stereotactic Radiosurgery for Patients with Two or Three Unresected Brain Metastases
Presenter: P. W. Sperduto Affiliation: Radiation Therapy Oncology Group Summary: Brain metastases develop in approximately 25% of all cancer patients. Management with stereotactic radiotherapy for patients with 3 or less solitary lesions remains an area of controversy. This preliminary analysis is of a group of patients treated with whole

A Phase II Randomized Trial of Synchronous Radiotherapy With Temozolomide in Brain Metastases
Presenter: E. Paraskevaidis Affiliation: Metaxas Cancer Hospital, Pireus, Greece Summary: The majority of patients with brain metastases has a dismal survival of approximately 4 months. Various strategies have been investigated, including whole brain radiation therapy (WBRT), craniotomy, stereotactic radiosurgery boost,